Amgen Inc. $AMGN Stock Sold by D.A. Davidson & CO.

Key Points

• D.A. Davidson & Co. reduced its Amgen stake by 1.2%, selling 2,579 shares and retaining 209,707 shares valued at approximately $88.4 million. Institutional investors collectively own 76.5% of the company.
• Amgen’s latest quarterly results exceeded expectations, with earnings per share of $6.29 versus the $5.62 consensus estimate and revenue of $10.05 billion, up 9.5% year over year.
• The company declared a quarterly dividend of $2.52 per share, equivalent to $10.08 annually and a 2.2% yield. Analysts maintain a consensus “Hold” rating with an average price target of $389.71, below the reported $451.83 share price.

D.A. Davidson & CO. reduced its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 209,707 shares of the medical research company's stock after selling 2,579 shares during the period. D.A. Davidson & CO.'s holdings in Amgen were worth $88,394,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its holdings in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. Bank of America Corp DE purchased a new stake in Amgen in the second quarter worth approximately $1,831,903,000. Wellington Management Group LLP boosted its holdings in Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company's stock worth $993,031,000 after purchasing an additional 2,514,254 shares during the last quarter. BlackRock Inc. grew its position in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Amgen by 702.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company's stock worth $647,126,000 after purchasing an additional 1,344,010 shares during the period. Institutional investors own 76.50% of the company's stock.

Amgen Stock Up 0.9%

AMGN opened at $451.83 on Thursday. The stock has a market cap of $244.27 billion, a price-to-earnings ratio of 28.08, a price-to-earnings-growth ratio of 3.21 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The firm's fifty day moving average is $418.95 and its 200 day moving average is $373.41. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $454.66.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion during the quarter, compared to analysts' expectations of $9.43 billion. During the same quarter last year, the business posted $6.02 earnings per share. The firm's revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Nancy Grygiel sold 2,970 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. UBS Group boosted their target price on shares of Amgen from $430.00 to $470.00 and gave the company a "buy" rating in a research note on Friday, October 9th. Robert W. Baird raised their price target on Amgen from $215.00 to $230.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 5th. BMO Capital Markets cut their price objective on Amgen from $450.00 to $415.00 and set a "market perform" rating for the company in a report on Monday, October 12th. Canaccord Genuity Group lifted their price objective on Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Finally, Jefferies Financial Group reiterated a "hold" rating and set a $410.00 price objective on shares of Amgen in a research report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $389.71.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported positive Phase 3 OASIZ-301 results for dazodalibep in Sjögren’s disease, showing statistically significant and clinically meaningful improvements in systemic disease activity and patient-reported dryness. The company will also present additional data for UPLIZNA, KRYSTEXXA and TAVNEOS, reinforcing the potential of its rare-disease and autoimmune pipeline. Amgen autoimmune disease data announcement
• Positive Sentiment: Goldman Sachs and TD Cowen reiterated Buy ratings, supporting the view that Amgen’s oncology, rare-disease and autoimmune portfolio can sustain growth. Goldman Sachs Buy rating TD Cowen Buy rating
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, providing continued income support for shareholders. The payment is scheduled for December 11 to shareholders of record on November 20. Amgen fourth-quarter dividend announcement
• Neutral Sentiment: Amgen will release third-quarter 2026 results after the U.S. market closes on November 3. The company has a four-quarter earnings-beat streak, but investors are focused on whether strong drug sales can offset pricing pressure, biosimilar competition and rising costs. Amgen third-quarter 2026 earnings webcast
• Negative Sentiment: The FDA issued a warning concerning promotional material for Amgen’s cancer drug Vectibix, creating regulatory and compliance risk. FDA warning over Vectibix promotion
• Negative Sentiment: Jefferies raised its price target to $428, which remains below the stock’s recently cited trading level and may signal limited near-term upside despite maintaining broader bullish sentiment. Jefferies Amgen price target

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.